TruVivo is an ideal platform for applications that require prolonged or repeated compound exposures, including the clearance of low-turnover compounds. Validation work by pharmaceutical partner, Boehringer Ingelheim, has demonstrated the potential for TruVivo to predict in vivo clearance.

To view their poster, click here.

The feeder cells are not liver-derived but are a mixture of primary human stromal and endothelial cells.

For each format, 24- and 96-well, the ratio of feeder cells to hepatocytes has been optimized to achieve human-relevant hepatocyte morphology and functionality. Optimal seeding densities for hepatocytes and feeder cells are provided.

The feeder cells have been growth-arrested to minimize cell expansion.

The total number of attached hepatocytes per well is lot-dependent. Based on initial seeding density, expect greater than or equal to 50% attachment. The calculated hepatocyte cell number per well for each lot is provided for data normalization.

For more information about how we calculate this value, click here.

Kits include enough media to accommodate daily medium changes for two weeks − however, the frequency of medium changes can be adapted to meet specific assay needs. For most culture work, it is recommended to change at least every two to three days. For applications that require prolonged compound exposures, plates can go up to seven days without changing the medium.

Typically, by day five, cell morphology and functionality have stabilized, and cells are ready for compound treatment. This can be extended to seven days if needed for workflow convenience.